Immunophotonics Announces 1st Patient Dosed in a Randomized Phase 2 Study at the University of Louisville
SAINT LOUIS, MISSOURI, USA, August 15, 2024 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, in collaboration with Dr. Robert CG Martin II, M.D, PhD, …